PMID- 35207305
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220301
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 11
IP  - 4
DP  - 2022 Feb 16
TI  - Impact of Glucocorticoid Cumulative Doses in a Real-Life Cohort of Patients 
      Affected by Giant Cell Arteritis.
LID - 10.3390/jcm11041034 [doi]
LID - 1034
AB  - OBJECTIVES: To describe the impact of cumulative glucocorticoid (GC) doses on 
      related adverse events (AEs) in giant cell arteritis (GCA) in a real-life 
      setting. METHODS: The medical charts of the last 139 consecutive GCA patients 
      followed in a tertiary centre were retrospectively analysed. The cumulative GC 
      doses were calculated, and the main GC-related AEs were collected during the 
      follow-up. RESULTS: After a median follow-up duration of 35.6 (2-111) months, the 
      median cumulative GC dose in the 139 patients was 9184 (1770-24,640) mg, and 131 
      patients (94%) presented at least one GC-related AE. Infections (63%) were the 
      most frequently reported GC-related AE, followed by metabolic events (63%), 
      including weight gain in 51% of them. Cardiovascular and neuropsychiatric events 
      occurred in 51% and 47% of patients, respectively. Osteoporotic fractures, 
      muscular involvement, digestive events, geriatric deterioration, skin fragility, 
      ophthalmologic complications and hypokalaemia were reported in <35% of patients. 
      Cardiovascular events (p = 0.01), osteoporotic fractures (p = 0.004), cataract 
      occurrence (p = 0.03), weight gain (p = 0.04) and infections (p = 0.01) were 
      significantly associated with GC cumulative doses > 9 g. Longer GC durations were 
      associated with cataract occurrence (p = 0.01), weight gain (p = 0.03) and 
      all-grade infections (p = 0.048), especially herpes zoster occurrence (p = 
      0.003). Neuropsychiatric and metabolic events appeared within the first months 
      after GC introduction, whereas herpes zoster recurred, and most cardiovascular 
      AEs emerged after 1 year. Geriatric events, especially osteoporotic fractures, 
      occurred 2 years after GC introduction. CONCLUSION: This study highlights how 
      frequent GC-related AEs are and the impact of prolonged GC and cumulative doses.
FAU - Castan, Paul
AU  - Castan P
AD  - Department of Internal Medicine, Caen University Hospital, Avenue de la Cote de 
      Nacre, 14000 Caen, France.
FAU - Dumont, Anael
AU  - Dumont A
AD  - Department of Internal Medicine, Caen University Hospital, Avenue de la Cote de 
      Nacre, 14000 Caen, France.
AD  - UFR de Sante, Caen University-Normandie, 14000 Caen, France.
FAU - Deshayes, Samuel
AU  - Deshayes S
AUID- ORCID: 0000-0001-8887-3233
AD  - Department of Internal Medicine, Caen University Hospital, Avenue de la Cote de 
      Nacre, 14000 Caen, France.
AD  - UFR de Sante, Caen University-Normandie, 14000 Caen, France.
FAU - Boutemy, Jonathan
AU  - Boutemy J
AD  - Department of Internal Medicine, Caen University Hospital, Avenue de la Cote de 
      Nacre, 14000 Caen, France.
FAU - Martin Silva, Nicolas
AU  - Martin Silva N
AD  - Department of Internal Medicine, Caen University Hospital, Avenue de la Cote de 
      Nacre, 14000 Caen, France.
FAU - Maigne, Gwenola
AU  - Maigne G
AD  - Department of Internal Medicine, Caen University Hospital, Avenue de la Cote de 
      Nacre, 14000 Caen, France.
FAU - Nguyen, Alexandre
AU  - Nguyen A
AD  - Department of Internal Medicine, Caen University Hospital, Avenue de la Cote de 
      Nacre, 14000 Caen, France.
AD  - UFR de Sante, Caen University-Normandie, 14000 Caen, France.
FAU - Gallou, Sophie
AU  - Gallou S
AD  - Department of Internal Medicine, Caen University Hospital, Avenue de la Cote de 
      Nacre, 14000 Caen, France.
FAU - Sultan, Audrey
AU  - Sultan A
AD  - Department of Internal Medicine, Caen University Hospital, Avenue de la Cote de 
      Nacre, 14000 Caen, France.
FAU - Aouba, Achille
AU  - Aouba A
AD  - Department of Internal Medicine, Caen University Hospital, Avenue de la Cote de 
      Nacre, 14000 Caen, France.
AD  - UFR de Sante, Caen University-Normandie, 14000 Caen, France.
FAU - de Boysson, Hubert
AU  - de Boysson H
AD  - Department of Internal Medicine, Caen University Hospital, Avenue de la Cote de 
      Nacre, 14000 Caen, France.
AD  - UFR de Sante, Caen University-Normandie, 14000 Caen, France.
LA  - eng
PT  - Journal Article
DEP - 20220216
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC8875204
OTO - NOTNLM
OT  - adverse events
OT  - cumulative doses
OT  - giant cell arteritis
OT  - glucocorticoids
OT  - tolerance
COIS- De Boysson received speaker/consulting fees from Roche-Chugai.
EDAT- 2022/02/26 06:00
MHDA- 2022/02/26 06:01
PMCR- 2022/02/16
CRDT- 2022/02/25 01:11
PHST- 2022/01/07 00:00 [received]
PHST- 2022/02/03 00:00 [revised]
PHST- 2022/02/10 00:00 [accepted]
PHST- 2022/02/25 01:11 [entrez]
PHST- 2022/02/26 06:00 [pubmed]
PHST- 2022/02/26 06:01 [medline]
PHST- 2022/02/16 00:00 [pmc-release]
AID - jcm11041034 [pii]
AID - jcm-11-01034 [pii]
AID - 10.3390/jcm11041034 [doi]
PST - epublish
SO  - J Clin Med. 2022 Feb 16;11(4):1034. doi: 10.3390/jcm11041034.